FDA follow-on biologics workshop
Executive Summary
FDA schedules public workshop on "follow-on protein products" for Sept. 14 and 15. "Because of the scientific complexity of protein pharmaceutical products, FDA intends to conduct an extensive public dialogue on the scientific issues relating to the development and approval of such products," the 1FDA notice of the workshop states. The workshop will not address legal or regulatory issues. An FDA/DIA meeting on follow-on biologics is expected to take place in 2005 (2"The Pink Sheet" Aug. 9, 2004, p. 10). The workshop will be held at the University of Maryland Shady Grove Conference Center in Rockville, Md. starting at 8:30 a.m. on Sept. 14 and at 8 a.m. on Sept. 15...
You may also be interested in...
Follow-On And Wait: FDA Defers Action On Sandoz’s Human Growth Hormone
Sandoz is presenting FDA's deferral of its decision on approval of the company's recombinant human growth hormone Omnitrope as essentially a tentative approval
FDA Follow-On Biologics Public Meeting Slated For Early ’05
FDA and the Drug Information Association are looking at dates in early 2005 for a public meeting on scientific issues surrounding the development of follow-on biologics
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”